Predicting risk of prostate specific antigen recurrence after radical prostatectomy with the center for prostate disease research and cancer of the prostate strategic urologic research endeavor databases

Journal of Urology

Volumn 166, Issue 4, 2001, Pages 1322-1327

  Moul, Judd W ^a   Connelly, Roger R ^b   Lubeck, Deborah P ^b   Bauer, John J ^b   Sun, Leon ^b   Flanders, Scott C ^b   Grossfeld, Gary D ^b   Carroll, Peter R ^b  

^a Center for Prostate Disease Research   (United States)

^b NONE

Author keywords

Prostatectomy; Prostatic neoplasms; Recurrence; Risk assessment

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; ARTICLE; BIOSTATISTICS; CALCULATION; CANCER RECURRENCE; CANCER RESEARCH; CANCER SCREENING; CORRELATION FUNCTION; DATA BASE; ETHNIC DIFFERENCE; HUMAN; MAJOR CLINICAL STUDY; MALE; OUTCOMES RESEARCH; PREDICTION; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; REGRESSION ANALYSIS; RISK ASSESSMENT; SCORING SYSTEM; SURVIVAL RATE;

EID: 0034827876     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0022-5347(05)65761-8     Document Type: Article

References (28)

1. Cancer statistics 2000
2. Population-based prostate cancer trends in the PSA-era: Data from the Surveillance, Epidemiology, and End Results (SEER) program
3. Clinical highlights from the National Cancer Database, 2000
4. Prostate specific antigen only progression of prostate cancer
5. Combination of prostate specific antigen, clinical stage, and Gleason score to predict pathologic stage of localized prostate cancer: A multi-institutional update
6. Evaluation of a nomogram for predicting pathological stage of men with clinically localized prostate cancer
7. An algorithm for predicting non-organ confined prostate cancer using the results obtained from sextant core biopsies with prostate specific antigen level
8. The role of transrectal ultrasound-guided biopsy-based staging, preoperative serum prostate specific antigen, and biopsy Gleason score in prediction of final pathologic diagnosis in prostate cancer
9. Selection of men at high risk for disease recurrence for experimental adjuvant therapy following radical prostatectomy
10. A multivariate analysis of clinical and pathological factors that predict for prostate specific antigen failure after radical prostatectomy for prostate cancer
11. Ki-67 expression is a prognostic marker of prostate cancer recurrence after radical prostatectomy
12. Elevated levels of apoptosis regulator proteins p53 and bcl-2 are independent prognostic biomarkers in surgically treated clinically localized prostate cancer
13. Stage T1-2 prostate cancer: A multivariate analysis of factors affecting the biochemical and clinical failures after radical prostatectomy
14. Biostatistical modeling using traditional variables and genetic biomarkers for predicting the risk of prostate carcinoma recurrence after radical prostatectomy
15. A preoperative nomogram for disease recurrence following radical prostatectomy for prostate cancer
16. CD34 immunohistochemical assessment of angiogenesis as a prognostic marker for prostate cancer recurrence after radical prostatectomy
17. Biostatistical modeling using traditional preoperative and pathological prognostic variables in the selection of men at high risk for disease recurrence after radical prostatectomy for prostate cancer
18. Statistical modeling using preoperative prognostic variables in predicting extracapsular extension and progression after radical prostatectomy for prostate cancer
19. Predictive value of decreased p27Kip1 protein expression for the recurrence-free and long-term survival of prostate cancer patients
20. Clinical utility of the percentage of positive prostate biopsies in defining biochemical outcome after radical prostatectomy for patients with clinically localized prostate cancer
21. The CaPSURE database: A methodology for clinical practice and research in prostate cancer
22. TNM classification of prostate cancer. Clinicopathologic correlations
23. Histological grading and clinical staging of prostate carcinoma
24. Regression models and life tables
25. Non-parametric estimation from incomplete observations
26. Emerging prognostic factors for outcome prediction in clinically localized prostate cancer: Prostate-specific antigen level, race, molecular markers and neural networks
27. Prostate biopsy: A wealth of information when done and interpreted correctly
28. Immediate hormonal therapy compared with observation after radical prostatectomy and pelvic lymphadenectomy in men with node-positive prostate cancer